Animal models of cholangiocarcinoma

Current Opinion in Gastroenterology

Volumn 29, Issue 3, 2013, Pages 312-318

  Ko, Kwang Suk ^a   Peng, Jian ^b   Yang, Heping ^c  

^a Ewha Womans University   (South Korea)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

carcinogen induced models; cholangiocarcinoma; genetically modified mouse models; orthotopic model; xenograft model

Indexed keywords

CARCINOGEN;

ANIMAL MODEL; BILE DUCT CARCINOMA; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER THERAPY; DISEASE ACTIVITY; EARLY DIAGNOSIS; GENETIC ENGINEERING; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENICITY; REVIEW; TRANSGENIC MOUSE; TUMOR XENOGRAFT;

ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; MICE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84876285700     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32835d6a3e     Document Type: Review

References (38)

1. Zhang J, Han C, Wu T. MicroRNA-26a promotes cholangiocarcinoma growth by activating b-catenin. Gastroenterology 2012; 143:246-256.
2. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010; 51:881-890.
3. Meng F, Wehbe-Janek H, Henson R, et al. Epigenetic regulation ofmicroRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 2008; 27:378-386.
4. Yamanaka S, Campbell NR, An F, et al. Coordinated effects ofmicroRNA-494 induce G2/M arrest in human cholangiocarcinoma. Cell Cycle 2012; 11:2729-2738.
5. Olaru AV, Ghiaur G, Yamanaka S, et al. MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology 2011; 54:2089-2098.
6. Zhang K, Chen D, Wang X, et al. RNA interference targeting slug increases cholangiocarcinoma cell sensitivity to cisplatin via upregulating PUMA. Int J Mol Sci 2011; 12:385-400.
7. Obchoei S, Weakley SM, Wongkham S, et al. Cyclophilin A enhances cell proliferation and tumours growth of liver fluke-associated cholangiocarcino-ma. Mol Cancer 2011; 10:102.
8. Hou YJ, Dong LW, Tan YX, et al. Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinoma. Lab Invest 2011; 91:1146-1157.
9. Pawar P, Ma L, Byon CH, et al. Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin Cancer Res 2009; 15:1288-1296.
10. Frampton GA, Lazcano EA, Li H, et al. Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents. Lab Invest 2010; 90:1325-1338.
11. DeMorrow S, Onori P, Venter J, et al. Neuropeptide Y inhibits cholangio-carcinoma cell growth and invasion. Am J Physiol Cell Physiol 2011; 300:C1078-C1089.
12. Lang M, Henson R, Braconi C, Patel T. Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver Int 2009; 29:670-677.
13. Tang T, Zheng JW, Chen B, et al. Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice. Hepatobiliary Pancreat Dis Int 2007; 6:303-307.
14. Blechacz BR, Smoot RL, Bronk SF, et al. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology 2009; 50:1861-1870.
15. Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009; 64:777-783.
16. Campbell DJ, Dumur CI, Lamour NF, et al. Novel organotypic culture model of cholangiocarcinoma progression. Hepatol Res 2012; 42:1119-1130.
17. Noda T, Shimoda M, Ortiz V, et al. Immunization with aspartate-(- hydroxylase-loaded dendritic cells produces antitumor effects in a rat model of intrahepatic cholangiocarcinoma. Hepatology 2012; 55:86-97.
18. Zhang Z, Oyesanya RA, Campbell DJ, et al. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy. Hepatology 2010; 52:975-986.
19. Sirica AE, Zhang Z, Lai GH, et al. A novel 'patient-like' model of cholangio-carcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology 2008; 47:1178-1190.
20. Lai GH, Zhang Z, Shen XN, et al. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology 2005; 129:2047-2057.
21. Yang H, Li TW, Peng J, et al. Mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. Gastroenterology 2011; 141:378-388.
22. Plengsuriyakarn T, Eursitthichai V, Labbunruang N, et al. Ultrasonography as a tool for monitoring the development and progression of cholangiocarcinoma in Opisthorchis viverrini/dimethylnitrosamine-induced hamsters. Asian Pac J Cancer Prev 2012; 13:87-90.
23. Chen T, Williams TD, Mally A, et al. Gene expression and epigenetic changes by furan in rat liver. Toxicology 2012; 292:63-70.
24. Radaeva S, Ferreira-Gonzalez A, Sirica AE. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. Hepatology 1999; 29:1453-1462.
25. Mansuroglu T, Ramadori P, Dudás J, et al. Expression of stem cell factor and its receptor c-Kit during the development of intrahepatic cholangiocarcinoma. Lab Invest 2009; 89:562-574.
26. Wójcik M, Ramadori P, Blaschke M, et al. Immunodetection of cyclooxygen-ase-2 (COX-2) is restricted to tissue macrophages in normal rat liver and to recruited mononuclear phagocytes in liver injury and cholangiocarcinoma. Histochem Cell Biol 2012; 137:217-233.
27. Fava G, Alpini G, Saccomanno S, et al. Leptin enhances cholangiocarcinoma cell growth. Cancer Res 2008; 68:6752-6761.
28. Yang H, Ko K, Xia M, et al. Induction of avian musculoaponeurotic fibrosar-coma proteins by toxic bile acid inhibits expression of glutathione synthetic enzymes and contributes to cholestatic liver injury in mice. Hepatology 2010; 51:1291-1301.
29. Yang H, Li TW, Ko KS, et al. Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes. Hepatology 2009; 49:860-870.
30. Yang H, Ramani K, Xia M, et al. Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications. Hepatology 2009; 49:1982-1991.
31. Heinrich S, Georgiev P, Weber A, et al. Partial bile duct ligation in mice: a novel model of acute cholestasis. Surgery 2011; 149:445-451.
32. Fickert P, Zollner G, Fuchsbichler A, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002; 123:1238-1251.
33. Farazi PA, Zeisberg M, Glickman J, et al. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res 2006; 66:6622-6627.
34. Kalamarides M, Niwa-Kawakita M, Leblois H, et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 2002; 16:1060-1065.
35. Lee KP, Lee JH, Kim TS, et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci USA 2010; 107:8248-8253.
36. Song H, Mak KK, Topol L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci USA 2010; 107:1431-1436.
37. Xu X, Kobayashi S, Qiao W, et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 2006; 116:1843-1852.
38. O'Dell MR, Huang JL, Whitney-Miller CL, et al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res 2012; 72:1557-1567.